Anzeige
Mehr »
Dienstag, 25.11.2025 - Börsentäglich über 12.000 News
Goldrausch 2.0: 60% Insideranteil - warum dieser Gold-Explorer als Geheimtipp gilt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1W1KK | ISIN: US23282W6057 | Ticker-Symbol: KK3A
Tradegate
25.11.25 | 21:04
58,00 Euro
-0,85 % -0,50
1-Jahres-Chart
CYTOKINETICS INC Chart 1 Jahr
5-Tage-Chart
CYTOKINETICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
57,5059,0022:13
57,0059,5022:00

Aktuelle News zur CYTOKINETICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
18.11.Cytokinetics, Incorporated: Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)3
17.11.Cytokinetics steps into Bristol Myers' shoes, funding heart registry ahead of commercial clash29
17.11.Cytokinetics, Incorporated: Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy12
CYTOKINETICS Aktie jetzt für 0€ handeln
13.11.Cytokinetics Gains 11.4% in a Week: Is There More Room for Growth?9
11.11.Cytokinetics: RBC Capital erhöht Kursziel auf 87 US-Dollar21
11.11.Cytokinetics stock price target raised to $87 from $82 at RBC Capital2
10.11.Cytokinetics, Incorporated: Cytokinetics Presents Additional Data from MAPLE-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 202596Three Late Breaking Science Presentations from MAPLE-HCM Provide Additional Data Including Responder Analyses, Patient Reported Outcomes, and Cardiac Biomarkers SOUTH SAN FRANCISCO, Calif., Nov....
► Artikel lesen
06.11.Cytokinetics outlines aficamten U.S. and EU launch plans with $1.2B in cash as FDA decision nears18
05.11.CYTOKINETICS INC - 10-Q, Quarterly Report2
31.10.Cytokinetics, Incorporated: Cytokinetics Announces Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 20255
22.10.Cytokinetics, Incorporated: Cytokinetics to Announce Third Quarter Results on November 5, 20253
17.10.Cytokinetics, Incorporated: Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)3
06.10.Cytokinetics stock price target raised to $82 from $71 at Barclays20
02.10.Can CYTK Clinch a Potential FDA Nod for Its Cardiovascular Drug?10
30.09.Cytokinetics stock maintains Buy rating as H.C. Wainwright cites exercise data6
29.09.Cytokinetics: Stifel bekräftigt "Buy"-Rating dank positiver Studiendaten zu Aficamten12
29.09.Cytokinetics stock maintains Buy rating at Stifel on promising aficamten data5
29.09.Cytokinetics, Incorporated: Cytokinetics Presents New Data Related to Aficamten at the HFSA Annual Scientific Meeting 20254
24.09.Cytokinetics, Incorporated: Cytokinetics Announces Call for Proposals for Its Eighth Annual Communications Grant Program7
23.09.Cytokinetics, Incorporated: Cytokinetics to Present at the Stifel 2025 Virtual Cardiometabolic Forum2
Weiter >>
90 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1